Steatohepatitis after chemotherapy for colorectal liver metastases (CASH);Steatohepatitis bei der Chemotherapie kolorektaler Lebermetastasen (CASH)

Pathologe

Volumn 32, Issue 4, 2011, Pages 330-335

  Tannapfel, A ^a   Reinacher Schick, A ^b   Flott Rahmel, B ^a  

^a INSTITUT FÜR PATHOLOGIE   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Chemotherapy; Colorectal carcinoma; Liver metastases; Sinusoidal obstruction syndrome; Steatohepatitis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; ELECTRON MICROSCOPY; FATTY LIVER; HUMAN; LIVER; LIVER TUMOR; LIVER VEIN OBSTRUCTION; METASTASIS; MULTIMODALITY CANCER THERAPY; NODULAR HYPERPLASIA; PATHOLOGY;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FATTY LIVER; FOCAL NODULAR HYPERPLASIA; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER; LIVER NEOPLASMS; MICROSCOPY, ELECTRON; NEOADJUVANT THERAPY; NEOPLASM STAGING;

EID: 79961208261     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-011-1434-2     Document Type: Article

References (33)

1. Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983-4990 (Pubitemid 46631400)
2. Brouquet A, Abdalla EK, Kopetz S et al (2011) High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29:1083-1090
3. Brunt EM (2001) Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21:3-16 (Pubitemid 32240482)
4. Brunt EM (2002) Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis 6:399-420 (Pubitemid 34755899)
5. Brunt EM, Janney CG, Di Bisceglie AM et al (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474 (Pubitemid 29420675)
6. Brunt EM, Ramrakhiani S, Cordes BG et al (2003) Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 16:49-56 (Pubitemid 36152686)
7. Brunt EM, Tiniakos DG (2002) Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 16:691-707
8. Chitturi S, Abeygunasekera S, Farrell GC et al (2002) NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373-379 (Pubitemid 34106377)
9. Church TS, Kuk JL, Ross R et al (2006) Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130:2023-2030 (Pubitemid 43816951)
10. Cortez-Pinto H, Moura MC de, Day CP (2006) Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 44:197-208 (Pubitemid 41772535)
11. Day CP, James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114:842-845
12. DeLeve LD, Shulman HM, McDonald GB (2002) Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22:27-42
13. Edmison J, McCullough AJ (2007) Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 11:75-104 (Pubitemid 46829977)
14. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21:17-26 (Pubitemid 32240483)
15. Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43:S99-S112
16. Gentilucci UV, Santini D, Vincenzi B et al (2006) Chemotherapy-induced steatohepatitis in colorectal cancer patients. J Clin Oncol 24:5467-5468
17. Karoui M, Penna C, Amin-Hashem M et al (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1-7 (Pubitemid 43054046)
18. Kishi Y, Zorzi D, Contreras CM et al (2010) Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17:2870-2876
19. Kleiner DE, Brunt EM, Van NM et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321 (Pubitemid 40770284)
20. Klinger M, Eipeldauer S, Hacker S et al (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35:515-520
21. Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M (2007) Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 27:423-433 (Pubitemid 46534563)
22. Mori T, Aisa Y, Shimizu T et al (2007) Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation. Am J Hematol 82:838-839 (Pubitemid 350194518)
23. Nakano H, Oussoultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118-124
24. Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37:1202-1219 (Pubitemid 36538699)
25. Nordlinger B, Van CE, Rougier P et al (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43:2037-2045 (Pubitemid 47380368)
26. Pawlik TM, Olino K, Gleisner AL et al (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860-868
27. Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460-466 (Pubitemid 38444550)
28. Rubbia-Brandt L, Lauwers GY, Wang H et al (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin- associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56:430-439
29. Rubbia-Brandt L, Tauzin S, Brezault C et al (2011) Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther 10:687-696
30. Schouten Velden AP van der, Punt CJ et al (2008) Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month. Eur J Surg Oncol 34:353-355 (Pubitemid 351312859)
31. Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072 (Pubitemid 46622116)
32. Zivkovic AM, German JB, Sanyal AJ (2007) Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 86:285-300 (Pubitemid 47256910)
33. Zorzi D, Laurent A, Pawlik TM et al (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94:274-286 (Pubitemid 46423843)